Panthera@theRutherford clinical trial partnership has commenced the first UK multicentre oncology trial in prostate cancer with ten more oncology trials in the pipeline

The first multisite oncology trial undertaken by the independent sector in the UK has started treating its first patient at the Rutherford Cancer Centre North East.

Gundersen Health System Partners with Kyruus to Propel Digital Access Transformation

Innovative Wisconsin-Based Healthcare Network Deploying Kyruus ProviderMatch® Platform to Modernize How Consumers Find Providers Online

2bPrecise Joins the Epic App Orchard to Bring Its Precision Medicine Insights to the Point of Care

2bPrecise™ announced its Precision Health™ platform is now available in the Epic App Orchard Gallery.

Exclusive interview with Professor Sir John Bell announced as Life Science Integrates celebrates ten years of Pharma Integrates

Life Science Integrates (LSI) is delighted to announce the exciting agenda for its flagship event, Pharma Integrates, held live online on 16th November 2021.

Curebase, LEVEL Announce Clinical Trial to Determine Whether Cannabinoids Can Help Veterans Sleep Better

Curebase, LEVEL Announce Clinical Trial to Determine Whether Cannabinoids Can Help Veterans Sleep Better

Swiss CDMO Invests in Powder Containment and Extends Spray Drying Capabilities

Aragen expects to ride wave of US biotech growth in 2022 – influx of discovery capital is surging demand for CDMO services

Company plans wide ranging investments and expansions to keep pace with demand driven by macro-changes and diversifying client base

Qlucore approved for listing on Nasdaq First North Growth Market

Qlucore AB (public) (“Qlucore” or “Company”) has today received approval of the application for listing of Qlucore shares on the Nasdaq First North Growth Market. The first day of trading of the shares will be 5th November 2021. Trading will be done with the ticker QCORE.

CMOs will account for four of the five top bio manufacturing capacities in 2025

230 Covid-19 supply agreements known, with demand for larger biocapacity remaining constrained as a consequence of the circa 1000 vaccines in development

The Community Blood Center (Appleton, WI) to roll out biolog-id’s technology to support platelet lifecycle management

The Community Blood Center is the latest regional blood center to embrace biolog-id’s technology. Biolog-id’s solution for platelet lifecycle management will be deployed to support the efficiency of platelet manufacturing, documentation, and inventory management.

Pillar VC and Petri Announce Winners of $200K Pitch Competition

Pillar VC and Petri have announced the winners of the $200K Pitch Competition that took place during the Founder-Led Biotech Summit, a free virtual event that brought together biotech founders, faculty, PhDs, scientists, investors, and executives to support the founder-led biotech movement.

CHARGEPOINT TECHNOLOGY APPOINTS NEW COO TO DRIVE FUTURE GROWTH

Birmingham Biotech and the University of Birmingham sign licensing agreement for anti-viral nasal spray against COVID-19

Birmingham Biotech Ltd, an innovator in diagnostic tests, protective nasal sprays and mobile medical facilities, and the University of Birmingham have signed a licensing agreement to commercialise a novel anti-viral nasal spray that protects against COVID-19.

Protheragen MedAI Upgrades CADD Platform to Accelerate Drug Design

Samsung Biologics Reports Strong Second Quarter 2021 Financial Results

CluePoints partners with ZS to provide best-in-class RBQM expertise and technology, increasing clinical trial efficiency and improving patient outcomes

CluePoints, the premier provider of risk-based quality management (RBQM) and data oversight software for clinical trials, has partnered with ZS, a global professional services firm with technology and analytics expertise in biopharma, to offer innovative capabilities in portfolio-level performance oversight.  The new partnership pairs a best-in-breed solutions company focused on study-level risk-based management with a pharmaceutical and biotech solutions provider with advanced capabilities in portfolio-level quality and operational oversight.

DFE Pharma Proudly Supports COVID-19 Vaccination Supply in Pakistan

Certara’s Simcyp™ COVID-19 Vaccine Model Named Finalist in Both the 2021 Citeline Awards and R&D 100 Awards

Certara’s Simcyp COVID-19 Vaccine Model uses biosimulation to improve decision-making and help optimize dosing regimens of COVID-19 vaccines. Certara calibrated its model using the structure of actual COVID-19 vaccines and validated it by replicating the published clinical data. The model, which is incorporated in Certara’s Vaccine Simulator™, addresses important questions such as differences in response with age and ethnicity, optimal timing between doses and expected duration of antibody response.

BOC Sciences Offers Pseudouridine and Its Derivatives for RNA Improvement

Biofourmis Earns FDA’s First-Ever Breakthrough Device Designation for a Novel Digital Therapeutic for Heart Failure

Biofourmis completed a proof of concept study for its heart failure digital therapeutic BiovitalsHF that met its endpoint of number of patients at 50% of optimal therapy. As a result, FDA has granted the DTx the first-ever Breakthrough Designation for a heart failure digital therapy.